Cantor Fitzgerald Estimates Humana FY2025 Earnings

Humana Inc. (NYSE:HUMFree Report) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Humana in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst S. James forecasts that the insurance provider will earn $16.17 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $395.00 price objective on the stock. The consensus estimate for Humana’s current full-year earnings is $16.11 per share.

Humana (NYSE:HUMGet Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%.

Several other equities research analysts have also weighed in on HUM. Morgan Stanley upped their price objective on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Jefferies Financial Group cut Humana from a “buy” rating to a “hold” rating and cut their price objective for the company from $519.00 to $253.00 in a report on Monday, October 7th. Piper Sandler boosted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Finally, Leerink Partners cut shares of Humana from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Humana presently has an average rating of “Hold” and a consensus target price of $302.70.

Check Out Our Latest Analysis on Humana

Humana Stock Performance

NYSE:HUM opened at $284.74 on Wednesday. The firm has a market capitalization of $34.29 billion, a PE ratio of 25.22, a price-to-earnings-growth ratio of 2.13 and a beta of 0.55. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 12-month low of $213.31 and a 12-month high of $411.80. The firm has a 50-day moving average price of $273.82 and a 200 day moving average price of $306.62.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.29% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HUM. State Street Corp raised its position in shares of Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after purchasing an additional 53,272 shares during the period. FMR LLC increased its stake in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Pzena Investment Management LLC raised its holdings in Humana by 8.1% during the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after buying an additional 187,903 shares during the period. Marshall Wace LLP lifted its stake in Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after buying an additional 774,085 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Humana by 2.1% in the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after buying an additional 24,842 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Stories

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.